Viking Global Investors is a hedge fund working with pooled investment vehicles on a global level. The company was founded in 1999 by Andreas Halvorsen...
Keep Reading →
May 20 - Hedge Funds, News - Comments
Is Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) going to burn you? In the 21st century investor’s toolkit, there are dozens of methods shareholders can...
Keep Reading →
August 27 - News - Comments
We maintain a database of quarterly 13F filings from hundreds of hedge funds and other notable investors. Our research has shown that this information...
Keep Reading →
August 27 - Hedge Funds - Comments
Judging by the numbers, Galena Biopharma Inc (NASDAQ:GALE) isn’t exactly a stock many would call great. Sure, shares are up more than 45% year-...
Keep Reading →
August 26 - News - Comments
Is Mylan Inc. (NASDAQ:MYL) a buy? To many investors, hedge funds are assumed to be overrated, old financial vehicles of an era lost to time. Although...
Keep Reading →
August 25 - News - Comments
Several weeks after the end of each quarter, hedge funds and other major investors are required to file 13Fs with the SEC to disclose many of their long...
Keep Reading →
August 19 - Hedge Funds - Comments
Will generic pharmaceutical makers like Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Perrigo Company (NYSE:PRGO) continue to be a value...
Keep Reading →
August 12 - News - Comments
Many market-watchers are scratching their heads about the pharmaceutical industry’s latest blockbuster deal. Although it had been expected to make...
Keep Reading →
August 12 - News - Comments
A patented drug is a cash cow for drug manufacturers. There are two ways to have a patented cash generating drug on a pharmaceutical company’s pipeline...
Keep Reading →
August 5 - News - Comments
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) hardly gets the attention it deserves. The Israel-based generic-pharmaceutical manufacturer supplies in...
Keep Reading →
August 1 - News - Comments
AstraZeneca plc (ADR) (NYSE:AZN)’s financial results have been on a downward spiral lately, as patent expirations have led to sharp declines in sales...
Keep Reading →
July 15 - News - Comments
Today’s investing environment is one that forces decisions to be made and, consequently, many errors. In so many cases, investors take an emotional...
Keep Reading →
July 10 - News - Comments
Pharma companies have been paying off generic drug makers so that cheap generic drugs do not enter the market. In a settlement case involving AbbVie Inc...
Keep Reading →
July 9 - News - Comments
Francis Chou, of Chou Associates Management, was recognized by Morningstar with the Fund Manager of the Decade award in 2004. We track his quarterly 13F...
Keep Reading →
July 9 - Hedge Funds - Comments
Niche biotech company Warner Chilcott Plc (NASDAQ:WCRX) has been looking for an exit strategy ever since announcing strategic alternatives back in August...
Keep Reading →
June 27 - News - Comments
A new Supreme Court ruling presents pharmaceutical companies with a tough choice — stop paying generic-drug producers to withhold generic options...
Keep Reading →
June 20 - News - Comments
When the FTC and the U.S. Supreme Court start breathing down your neck it’s not a pleasant thing, and could become very expensive for certain companies...
Keep Reading →
June 18 - News - Comments
Nothing interests a value investor more than bad news. Where there’s a lack of enthusiasm, there’s usually a cheap stock. Hospira, Inc. (...
Keep Reading →
June 14 - News - Comments
Generic-drug makers are always on the hunt for the next branded drug to take down. But they can’t just go about launching copycats of every drug...
Keep Reading →
June 13 - News - Comments
Searching for potential stock investments can be a daunting task. With so many stocks to choose from – more than 2,300 listed on the NYSE and around...
Keep Reading →
June 13 - Hedge Funds - Comments
Five years ago, Viropharma Inc (NASDAQ:VPHM) had everything going for it. Sales of the company’s lead drug, Vancocin — an FDA-approved treatment...
Keep Reading →
June 12 - News - Comments
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stirred the merger and acquisition space once again with its announcement that it is about to acquire multinational...
Keep Reading →
June 10 - News - Comments
Generic-drug makers have considerable tailwinds, making their outperformance in the past year unsurprising. However, most companies within this sub-...
Keep Reading →
June 6 - News - Comments
Recently, Actavis Inc (NYSE:ACT) announced that it would acquire Warner Chilcott Plc (NASDAQ:WCRX) for around $8.5 billion in total consideration. Since...
Keep Reading →
May 30 - News - Comments
Charles Schwab Investment Management is one of the largest asset management companies, having assets worth $217 billion under management as on March 31...
Keep Reading →
May 29 - News - Comments
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has built a unique, winning drug business by acquiring underperforming niche product franchises and incorporating...
Keep Reading →
May 28 - News - Comments
Currently, a majority of pharma companies are facing the issue of generic competition. This has forced them to either expand their footprints in different...
Keep Reading →
May 28 - News - Comments
Raising the minimum wage has become a hot-button issue in the U.S. recently, with President Obama having called for a raise in the federal minimum wage...
Keep Reading →
May 28 - News - Comments
Generic pharmaceutical manufacturer Actavis Inc (NYSE:ACT) made headlines after confirming that it has entered into early stage discussions with Ireland...
Keep Reading →
May 20 - News - Comments
Editor’s Note: Warner Chilcott Plc (NASDAQ:WCRX), Actavis Inc (NYSE:ACT) Actavis to buy Warner Chilcott in $5 billion stock deal (Reuters) Generic...
Keep Reading →
May 20 - News - Comments
News that Montreal-based Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was in talks to merge with Parsippany, New Jersey-based Actavis Inc (NYSE:ACT) emerged...
Keep Reading →
May 15 - News - Comments
Actavis Inc (NYSE:ACT), the largest generic drug company in the US, just got even bigger. In a deal valued at $8.5 billion, Actavis Inc (NYSE:ACT) has...
Keep Reading →
May 1 - News - Comments
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), a pharmaceuticals company that makes money off of branded drugs as well as generics, is an interesting...
Keep Reading →
April 23 - News - Comments
One of the best places to be fully invested these days is pharmaceuticals. Over the last year the biggest drug makers, like Pfizer Inc. (NYSE:PFE), Johnson...
Keep Reading →
April 2 - News - Comments
U.S. generics firm Actavis Inc (NYSE:ACT), previously Watson Pharmaceuticals, reported a strong jump in its revenues in the fourth quarter and total earnings...
Keep Reading →
March 17 - News - Comments
One under-the-radar drug recently lost its patent protection and the result could have huge ramifications for the company that tried to fight the onslaught...
Keep Reading →
March 15 - News - Comments
